IRIS PubliCatt

Hohaus, Stefan
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.768
NA - Nord America 5.400
AS - Asia 1.619
AF - Africa 42
SA - Sud America 28
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.364
DE - Germania 1.989
SE - Svezia 1.056
CN - Cina 904
PL - Polonia 672
IT - Italia 531
UA - Ucraina 453
SG - Singapore 280
FR - Francia 254
IE - Irlanda 244
GB - Regno Unito 212
ID - Indonesia 157
FI - Finlandia 130
IN - India 130
RU - Federazione Russa 108
TR - Turchia 48
CI - Costa d'Avorio 34
CA - Canada 31
BE - Belgio 26
JP - Giappone 26
AU - Australia 21
VN - Vietnam 21
CZ - Repubblica Ceca 20
IR - Iran 20
BR - Brasile 14
CH - Svizzera 12
NL - Olanda 11
RO - Romania 10
ES - Italia 8
CO - Colombia 7
HK - Hong Kong 7
MY - Malesia 7
GR - Grecia 6
IL - Israele 5
AT - Austria 4
EU - Europa 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
CU - Cuba 3
DK - Danimarca 3
PT - Portogallo 3
ZA - Sudafrica 3
BD - Bangladesh 2
BG - Bulgaria 2
CL - Cile 2
CY - Cipro 2
EC - Ecuador 2
KR - Corea 2
LV - Lettonia 2
MX - Messico 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AR - Argentina 1
BN - Brunei Darussalam 1
DZ - Algeria 1
GH - Ghana 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
SI - Slovenia 1
TH - Thailandia 1
UY - Uruguay 1
Totale 12.883
Salva come PNG Salva come JPEG
Città #
Chandler 1.057
Warsaw 663
Ashburn 425
Jacksonville 344
Dublin 239
San Mateo 227
Nanjing 226
Ann Arbor 207
Fairfield 199
Woodbridge 198
Dearborn 196
Houston 193
Singapore 182
Wilmington 182
Jakarta 154
New York 135
Nürnberg 128
Milan 115
Seattle 105
Cattolica 98
Bremen 90
Moscow 85
Nanchang 85
Beijing 81
Rome 80
Redmond 77
Lawrence 74
Boston 71
Redwood City 70
Los Angeles 66
Munich 64
Princeton 58
Kunming 56
Marseille 56
Chicago 52
Cambridge 47
Lancaster 46
Izmir 39
Helsinki 37
Norwalk 35
Abidjan 34
Hebei 33
Hangzhou 32
Mountain View 31
Shanghai 31
Shenyang 30
Zhengzhou 30
Boardman 28
Jiaxing 28
Auburn Hills 25
Tianjin 25
Fremont 24
Leawood 24
Brussels 23
Changsha 23
Guangzhou 22
University Park 21
Hefei 20
London 18
Jinan 16
Augusta 15
Brno 15
Pune 14
Falls Church 13
Florence 13
Costa Mesa 12
Dong Ket 11
Lanzhou 10
Andover 9
Hanoi 9
Monmouth Junction 9
Berlin 8
Kish 8
Philadelphia 8
San Diego 8
Simi Valley 8
Sydney 8
Washington 8
Alghero 7
Chengdu 7
Edinburgh 7
Kraków 7
São Paulo 7
Bogotá 6
Changchun 6
Detroit 6
Enterprise 6
Mumbai 6
Phoenix 6
Verona 6
Ypsilanti 6
Buffalo 5
Frankfurt am Main 5
Hyderabad 5
Jesi 5
Kocaeli 5
Las Vegas 5
Naples 5
Ningbo 5
Sacramento 5
Totale 7.374
Salva come PNG Salva come JPEG
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 350
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 301
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy 282
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 264
Fanconi anemia gene variants in therapy-related myeloid neoplasms 256
Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients 235
THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA 228
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 206
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 181
Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 173
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 166
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 165
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 149
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 145
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 143
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 135
Why methylation is not a marker predictive of response to hypomethylating agents 134
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 133
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 133
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 132
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 131
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 130
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 127
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 125
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 124
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 122
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 119
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 119
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 118
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 114
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 113
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 111
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 111
Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). 110
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 109
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 109
Iron in Hodgkin's lymphoma 108
Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience 106
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 106
Epigenetic changes in therapy-related MDS/AML 104
A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia 103
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 101
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 101
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 99
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 99
Intravascular large B-cell lymphoma presenting as slowly progressive paraparesis with normal MRI features 98
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 98
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 98
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 98
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 96
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 96
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 96
Outcome of therapy-related myeloid neoplasms treated with azacitidine 94
PU.1 and CEBPA expression in acute myeloid leukemia. 94
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 93
Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients 93
Primary multifocal lymphoma of peripheral nervous system: Case report and review of the literature 93
Intravascular large-B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. 92
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 90
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 90
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 90
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 90
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 88
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 88
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 87
Clonal evolution in therapy-related neoplasms 87
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 86
Prognostic factors in hodgkin lymphoma 85
Small lymphocytic lymphoma in a patient with Fabry disease 84
Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3 84
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. 84
Mantle cell lymphoma relapsing at the lymphedematous arm 84
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 84
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 83
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 82
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment 82
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 81
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 79
Small lymphocytic lymphoma in a patient with Fabry disease 78
FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) 78
Desensitization to thalidomide in a patient with multiple myeloma 77
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 77
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 77
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 77
Burkitt's lymphoma of the breast metastatic to the ovary diagnosed during pregnancy 76
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma 76
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 75
Dural MALT Lymphoma Detected by 11C-Methionine PET/CT 75
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 74
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 72
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 72
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma 71
Muscle Recurrence of a Primarily Nodal Follicular Lymphoma Studied by Contrast-Enhanced 18F-FDG PET/CT 70
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 69
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 68
The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL) 67
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 65
Burkitt lymphoma as fourth neoplasia in a patient affected by cowden syndrome with a novel PTEN germline pathogenic variant 64
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy 63
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients 63
Totale 11.261
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.811
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.761 0 0 181 205 201 248 190 83 173 135 209 136
2020/20211.532 50 184 52 127 182 147 180 37 149 83 290 51
2021/20221.311 154 113 22 54 86 36 38 207 64 105 211 221
2022/20232.909 392 403 207 511 180 358 142 232 310 49 85 40
2023/20241.313 56 390 42 66 39 207 52 87 11 39 153 171
2024/2025459 100 115 244 0 0 0 0 0 0 0 0 0
Totale 13.072